Pasireotide, Everolimus and Selective Internal Radioembolization Therapy for Unresectable Hepatic Me

Whilst checking on some of the SRX trials, I came across this.

https://clinicaltrials.gov/ct2/show/NCT01469572

Have to assume they have recruited the number required.

This study is ongoing, but not recruiting participants.​

Sponsor:​

Emory University​

Collaborator:​

Novartis​

Information provided by (Responsible Party):​

Bassel El-Rayes, Emory University​

​

---------------------------​

	Column 1	Column 2
0	Enrollment:	13
1	Study Start Date:	December 2011
2	Estimated Study Completion Date:	March 2017
3	Estimated Primary Completion Date:	December 2016 (Final data collection date for primary outcome measure)

​

This is the interesting aspect:- (bold is mine)​

The purpose of this study is to see the safety and activity of using pasireotide, everolimus and radioembolization (Selective Internal Radioembolization Therapy-SIRT) in the treatment of neuroendocrine tumors (carcinoid) that has spread to the liver. Both everolimus or radioembolization are considered "standard of care" regimens in patients with liver lesions from neuroendocrine tumors.​

​

​

SOC - I was not aware that SIRT as considered SOC for any cancer.​

​